A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis

Atsushi Sakuraba, Toshiro Sato, Makoto Naganuma, Yuichi Morohoshi, Katsuyoshi Matsuoka, Nagamu Inoue, Hiromasa Takaishi, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC). Its original weekly treatment schedule is effective in about 70% of active UC. However, it takes about 3-4 weeks to achieve remission, and the efficacy of a more frequent treatment schedule has not been elucidated yet. We performed a pilot open-labeled prospective, randomized, controlled study comparing weekly and an intensive treatment schedule with three treatment sessions per week in the first 2 weeks. Methods. Thirty active UC patients with moderate disease activity were prospectively and randomly assigned to receive the original or the intensive treatment schedule for a total of ten sessions. The proportion of the patients achieving remission and the time to achieve remission among them was compared between the two groups. The incidences of adverse effects were also compared between the two groups. Results. The rate of inducing remission in the original and intensive treatment group was 66.7% and 80%, respectively (P = 0.25, NS). The time to achieve remission was 27.2 days in the original group and 10.7 days in the intensive group (P = 0.04). Adverse effects were observed in two patients in each groups (NS). Conclusions. Intensive treatment with GMAis an efficacious and safe treatment for active UC. Because it induces rapid remission, it may be a more ideal treatment regimen than the conventional weekly treatment.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalJournal of Gastroenterology
Volume43
Issue number1
DOIs
Publication statusPublished - 2008 Jan

Fingerprint

Blood Component Removal
Ulcerative Colitis
Granulocytes
Adsorption
Monocytes
Prospective Studies
Appointments and Schedules
Therapeutics

Keywords

  • Granulocyte and monocyte adsorption apheresis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{9e04f86dd8f242a18b0d7f4ae609da18,
title = "A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis",
abstract = "Background. Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC). Its original weekly treatment schedule is effective in about 70{\%} of active UC. However, it takes about 3-4 weeks to achieve remission, and the efficacy of a more frequent treatment schedule has not been elucidated yet. We performed a pilot open-labeled prospective, randomized, controlled study comparing weekly and an intensive treatment schedule with three treatment sessions per week in the first 2 weeks. Methods. Thirty active UC patients with moderate disease activity were prospectively and randomly assigned to receive the original or the intensive treatment schedule for a total of ten sessions. The proportion of the patients achieving remission and the time to achieve remission among them was compared between the two groups. The incidences of adverse effects were also compared between the two groups. Results. The rate of inducing remission in the original and intensive treatment group was 66.7{\%} and 80{\%}, respectively (P = 0.25, NS). The time to achieve remission was 27.2 days in the original group and 10.7 days in the intensive group (P = 0.04). Adverse effects were observed in two patients in each groups (NS). Conclusions. Intensive treatment with GMAis an efficacious and safe treatment for active UC. Because it induces rapid remission, it may be a more ideal treatment regimen than the conventional weekly treatment.",
keywords = "Granulocyte and monocyte adsorption apheresis, Ulcerative colitis",
author = "Atsushi Sakuraba and Toshiro Sato and Makoto Naganuma and Yuichi Morohoshi and Katsuyoshi Matsuoka and Nagamu Inoue and Hiromasa Takaishi and Haruhiko Ogata and Yasushi Iwao and Toshifumi Hibi",
year = "2008",
month = "1",
doi = "10.1007/s00535-007-2129-6",
language = "English",
volume = "43",
pages = "51--56",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis

AU - Sakuraba, Atsushi

AU - Sato, Toshiro

AU - Naganuma, Makoto

AU - Morohoshi, Yuichi

AU - Matsuoka, Katsuyoshi

AU - Inoue, Nagamu

AU - Takaishi, Hiromasa

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Hibi, Toshifumi

PY - 2008/1

Y1 - 2008/1

N2 - Background. Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC). Its original weekly treatment schedule is effective in about 70% of active UC. However, it takes about 3-4 weeks to achieve remission, and the efficacy of a more frequent treatment schedule has not been elucidated yet. We performed a pilot open-labeled prospective, randomized, controlled study comparing weekly and an intensive treatment schedule with three treatment sessions per week in the first 2 weeks. Methods. Thirty active UC patients with moderate disease activity were prospectively and randomly assigned to receive the original or the intensive treatment schedule for a total of ten sessions. The proportion of the patients achieving remission and the time to achieve remission among them was compared between the two groups. The incidences of adverse effects were also compared between the two groups. Results. The rate of inducing remission in the original and intensive treatment group was 66.7% and 80%, respectively (P = 0.25, NS). The time to achieve remission was 27.2 days in the original group and 10.7 days in the intensive group (P = 0.04). Adverse effects were observed in two patients in each groups (NS). Conclusions. Intensive treatment with GMAis an efficacious and safe treatment for active UC. Because it induces rapid remission, it may be a more ideal treatment regimen than the conventional weekly treatment.

AB - Background. Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC). Its original weekly treatment schedule is effective in about 70% of active UC. However, it takes about 3-4 weeks to achieve remission, and the efficacy of a more frequent treatment schedule has not been elucidated yet. We performed a pilot open-labeled prospective, randomized, controlled study comparing weekly and an intensive treatment schedule with three treatment sessions per week in the first 2 weeks. Methods. Thirty active UC patients with moderate disease activity were prospectively and randomly assigned to receive the original or the intensive treatment schedule for a total of ten sessions. The proportion of the patients achieving remission and the time to achieve remission among them was compared between the two groups. The incidences of adverse effects were also compared between the two groups. Results. The rate of inducing remission in the original and intensive treatment group was 66.7% and 80%, respectively (P = 0.25, NS). The time to achieve remission was 27.2 days in the original group and 10.7 days in the intensive group (P = 0.04). Adverse effects were observed in two patients in each groups (NS). Conclusions. Intensive treatment with GMAis an efficacious and safe treatment for active UC. Because it induces rapid remission, it may be a more ideal treatment regimen than the conventional weekly treatment.

KW - Granulocyte and monocyte adsorption apheresis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=40149093891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149093891&partnerID=8YFLogxK

U2 - 10.1007/s00535-007-2129-6

DO - 10.1007/s00535-007-2129-6

M3 - Article

C2 - 18297436

AN - SCOPUS:40149093891

VL - 43

SP - 51

EP - 56

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 1

ER -